Analysis of antibody neutralisation activity against SARS-CoV-2 variants and seasonal human coronaviruses NL63, HKU1, and 229E induced by three different COVID-19 vaccine platforms

Cantoni, D. et al. (2023) Analysis of antibody neutralisation activity against SARS-CoV-2 variants and seasonal human coronaviruses NL63, HKU1, and 229E induced by three different COVID-19 vaccine platforms. Vaccines, 11(1), 58. (doi: 10.3390/vaccines11010058) (PMID:36679903) (PMCID:PMC9864028)

[img] Text
284954.pdf - Published Version
Available under License Creative Commons Attribution.



Coronaviruses infections, culminating in the recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic beginning in 2019, have highlighted the importance of effective vaccines to induce an antibody response with cross-neutralizing activity. COVID-19 vaccines have been rapidly developed to reduce the burden of SARS-CoV-2 infections and disease severity. Cross-protection from seasonal human coronaviruses (hCoVs) infections has been hypothesized but is still controversial. Here, we investigated the neutralizing activity against ancestral SARS-CoV-2 and the variants of concern (VOCs) in individuals vaccinated with two doses of either BNT162b2, mRNA-1273, or AZD1222, with or without a history of SARS-CoV-2 infection. Antibody neutralizing activity to SARS-CoV-2 and the VOCs was higher in BNT162b2-vaccinated subjects who were previously infected with SARS-CoV-2 and conferred broad-spectrum protection. The Omicron BA.1 variant was the most resistant among the VOCs. COVID-19 vaccination did not confer protection against hCoV-HKU1. Conversely, antibodies induced by mRNA-1273 vaccination displayed a boosting in their neutralizing activity against hCoV-NL63, whereas AZD1222 vaccination increased antibody neutralization against hCoV-229E, suggesting potential differences in antigenicity and immunogenicity of the different spike constructs used between various vaccination platforms. These data would suggest that there may be shared epitopes between the HCoVs and SARS-CoV-2 spike proteins.

Item Type:Articles
Additional Information:The Temperton group (N.T., D.C., C.D.G. and M.M.N.) is funded by the Wellcome Trust (GB-CHC-210183), the MRC (MC_PC_19060) and MRC/NIHR (MC_PC_20016). S.L. and J.H. are funded by MC_UU_12014/12. L.L. was supported by the Scientific Direction of San Raffaele Scientific Institute (Immuno-COVID) and ANR France (MUCOLUNG).
Keywords:SARS-CoV-2, seasonal, HKU1, 229E, NL63, neutralisation.
Glasgow Author(s) Enlighten ID:Hughes, Dr Joseph and Cantoni, Dr Diego and Lytras, Spyros
Creator Roles:
Cantoni, D.Conceptualization, Methodology, Investigation, Data curation, Writing – original draft, Writing – review and editing
Lytras, S.Investigation, Writing – review and editing
Hughes, J.Investigation, Writing – review and editing
Authors: Cantoni, D., Siracusano, G., Mayora-Neto, M., Pastori, C., Fantoni, T., Lytras, S., Di Genova, C., Hughes, J., on behalf of the Ambulatorio Medico San Luca Villanuova Group, , Lopalco, L., and Temperton, N.
College/School:College of Medical Veterinary and Life Sciences > School of Infection & Immunity > Centre for Virus Research
Journal Name:Vaccines
ISSN (Online):2076-393X
Published Online:27 December 2022
Copyright Holders:Copyright © 2022 The Authors
First Published:First published in Vaccines 11(1): 58
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
172630014Cross-Cutting Programme – Viral Genomics and Bioinformatics (Programme 9)David RobertsonMedical Research Council (MRC)MC_UU_12014/12III - Centre for Virus Research